Novel DPP1 Inhibitor Improves Bronchiectasis Outcomes

(MedPage Today) -- Treatment with the novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor brensocatib prolonged time to first exacerbation for patients with non-cystic fibrosis bronchiectasis, and led to fewer exacerbations overall, a randomized...